Nasdaq IPOs

Is your client excited about new IPO stocks hitting the market like Robinhood (HOOD), but you’re unsure how to approach the conversation? Considering the fanfare around major IPOs, they can be hard to ignore — but it isn’t always easy to decide whether to invest in one or not.

Following on from a slower IPO arrival, shares in the popular investing app Robinhood (HOOD) have been soaring - illustrating the influence of the platform and its band of merry retail investors. 

Following a fast-paced July, Nasdaq anticipates robust activity for initial public offerings (IPOs) this fall.

Robinhood (HOOD) will begin trading on the Nasdaq. This is the most eagerly anticipated offering of the year, for sure, but in many ways may be the most interesting for a long time. So what can traders and investors expect?

Robinhood is no ordinary company. Here’s what you need to know about one of the most high-profile IPOs of 2021.

The global market for initial public offerings was off to a great start this year and is still running hot.There have been 250 IPOs priced this year, up 190.7% from last year, per renaissancecapital. Total proceeds raised are $89.0 billion, up 232.2% from last year. About

Founder SPAC, a blank check company targeting the cloud and other digital transformation sectors, filed on Monday with the SEC to raise up to $275 million in an initial public offering. The Houston, TX-based company plans to raise $275 million by offering 27.5 million units at $

Neo Technology Acquisition, a blank check company targeting businesses in Asia and North America, filed on Monday with the SEC to raise up to $40 million. The New York, NY-based company plans to raise $40 million by offering 4 million units at $10. Each unit consists of one share

Ocean Biomedical, a preclinical biotech developing therapies for cancer, infections, and other diseases, revised the terms of its upcoming IPO on Monday.The Providence, RI-based company now plans to raise $50 million by offering 6.3 million shares at a price range of $7 to $9. Th

Nuvalent, a preclinical oncology biotech developing small molecule kinase inhibitors, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $151 million by offering 8.9 million shares at a price range of $16 to $18. At the midpoint of the proposed

Tenaya Therapeutics, a preclinical biotech developing multiple therapies to treat heart disease, announced terms for its IPO on Monday.The South San Francisco, CA-based company plans to raise $150 million by offering 10 million shares at a price range of $14 to $16. At the midpoi

RxSight, a commercial-stage provider of post-cataract intraocular lens platform, announced terms for its IPO on Monday. The Aliso Viejo, CA-based company plans to raise $125 million by offering 7.4 million shares at a price range of $16 to $18. At the midpoint of the proposed ra

Rani Therapeutics, which develops ingestible capsules for oral dosing of medication, announced terms for its IPO on Monday.The San Jose, CA-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14 to $16. At the midpoint of the proposed ran

Rani Therapeutics, which develops ingestible capsules for oral dosing of medication, announced terms for its IPO on Monday.The San Jose, CA-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14 to $16. At the midpoint of the proposed ran

MaxCyte, which provides cell engineering devices and services, announced terms for its IPO on Monday.The Gaithersburg, MD-based company plans to raise $150 million by offering 12 million shares at a price range of $11.50 to $13.50. The company is currently listed on London's

The Better Being Co., which sells vitamins and supplements under the Solaray, KAL, and other brands, announced terms for its IPO on Monday. The Salt Lake City, UT-based company plans to raise $200 million by offering 12.5 million shares at a price range of $15 to $17. At the mid

Duolingo, an online language learning platform, raised the proposed deal size for its upcoming IPO on Monday.The Pittsburgh, PA-based company now plans to raise $498 million by offering 5.1 million shares (28% secondary) at a price range of $95 to $100. The company had previously

Omega Therapeutics, a preclinical biotech developing gene therapies for oncology and other diseases, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $126 million by offering 7.4 million shares at a price range of $16 to $18. At the midpoint

Immuneering, a preclinical biotech targeting signaling pathways to treat cancer and neurological diseases, announced terms for its IPO on Monday.The Cambridge, MA-based company plans to raise $105 million by offering 7 million shares at a price range of $14 to $16. At the midpoin

Candel Therapeutics, a Phase 3 biotech developing oncolytic viral immunotherapies for cancer, lowered the proposed deal size for its upcoming IPO on Monday.The Needham, MA-based company now plans to raise $72 million by offering 9 million shares at $8. The company had previously